Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01698905
Recruitment Status : Active, not recruiting
First Posted : October 3, 2012
Last Update Posted : November 14, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )